Regenxbio (RGNX) Tops Q4 EPS by $1.96

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of $6.67, $1.96 better than the analyst estimate of $4.71. Revenue for the quarter came in at $398.7 million versus the consensus estimate of $271.74 million.

Based on its current operating plan, REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $849.3 million as of December 31, 2021 to fund its operations, including the completion of its internal manufacturing capabilities and clinical advancement of its product candidates, into 2025.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Reading (RDI) Tops Q2 EPS by 4c